Brivaracetam Suppliers & Bulk Manufacturers

Available Forms: Tablet/ Oral Solution / Injection

Available Strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 10 mg/mL, 50 mg/5 mL

Reference Brands: Briviact (USA/EU)

Category: Neurology

Brivaracetam is an antiepileptic drug that works by binding to the synaptic vesicle protein 2A (SV2A) in the brain, helping control seizure activity. It’s used for the treatment of partial-onset seizures in patients aged one month and older. Brivaracetam is known for rapid brain penetration, fewer interactions, and better tolerability compared to levetiracetam.

Product Description:

Brivaracetam binds synaptic vesicle protein 2A, the same target as levetiracetam, but with roughly fifteen to thirty times higher affinity and more selectively — it has none of levetiracetam's effect on high-voltage calcium channels. The higher affinity and greater lipophilicity give faster brain penetration, which is why it can be started at a therapeutic dose without titration and why an intravenous form is useful when rapid effect is needed.

It is used for focal-onset seizures, as monotherapy or add-on depending on the market. Behavioural adverse effects — irritability, aggression, low mood — appear to be less frequent than with levetiracetam, and switching patients who could not tolerate levetiracetam for that reason is a common clinical use. Combining the two adds nothing, since they share the target. Rifampicin lowers exposure, and brivaracetam raises carbamazepine-epoxide levels.

Sourcing notes. Generic entry is recent and its timing differs between markets, so patent and exclusivity status should be confirmed country by country before any quotation. It is a Schedule V controlled substance in the US, which brings record-keeping and import registration obligations there even though most other markets do not schedule it. The injection and oral solution are separate registrations from the tablets, and the oral solution is what paediatric programmes buy.